Phosphorylation of vimentin is an intermediate step in protein kinase C-mediated glycoconjugate secretion.
We have previously shown that fibroblasts from patients with cystic fibrosis (CF) display a higher response to 4 beta-phorbol 12-myristate 13-acetate (PMA) than control fibroblasts for stimulation of both protein kinase C (PKC) cytosol-to-membrane translocation and glycoconjugate secretion. In this study we took advantage of these cells with differential responsiveness to PMA to investigate the endogenous substrate(s) involved in PKC stimulation of glycoconjugate secretion after verification of cystic fibrosis transmembrane conductance regulator gene expression in control and CF fibroblasts. We show that a 57-kDa protein that was associated with cytoskeleton and was identified as vimentin by immunoblotting emerged as a good candidate for mediating PKC stimulation of glycoconjugate secretion. 1) Its phosphorylation by PMA was abolished by PKC inhibition or depletion. 2) In both control and CF fibroblasts, the PMA-induced increase in its phosphorylation preceded the phorbol ester stimulation of glycoconjugate secretion. 3) For both processes, the concentration-response curves were superimposable, with higher maximal levels for CF fibroblasts relative to controls. 4) PMA-stimulated 57-kDa protein phosphorylation, like PMA-stimulated glycoconjugate secretion, was significantly increased by Ca2+. 5) Increased PMA phosphorylation of the 57-kDa protein as a result of okadaic acid inhibition of intracellular phosphatases was reflected in increased PMA stimulation of glycoconjugate secretion. In conclusion, 1) PMA phosphorylation of a cytoskeletal 57-kDa protein, identified as vimentin, appears to be an intermediate step in PKC stimulation of constitutive glycoconjugate secretion in human skin fibroblasts; and 2) this process is impaired in CF disease.
Bertrand
F
F
Laboratoire de Biochimie-Biologie Cellulaire, Institut National de la Santé et de la Recherche Médicale Unité 402, Faculté de Médecine Saint-Antoine, Paris, France.
Veissiere
D
D
Hermelin
B
B
Paul
A
A
Capeau
J
J
Picard
J
J
Cherqui
G
G
D001483:Base Sequence; D002478:Cells, Cultured; D003550:Cystic Fibrosis / Q000378:metabolism* / Q000473:pathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005347:Fibroblasts / Q000378:metabolism; D006001:Glycoconjugates / Q000378:metabolism*; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D015335:Molecular Probes / Q000235:genetics; D008969:Molecular Sequence Data; D010766:Phosphorylation; D016133:Polymerase Chain Reaction; D011493:Protein Kinase C / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D012016:Reference Values; D012867:Skin / Q000378:metabolism* / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014158:Transcription, Genetic; D014746:Vimentin / Q000378:metabolism*
C505032:CFTR protein, human; D006001:Glycoconjugates; D008565:Membrane Proteins; D015335:Molecular Probes; D012333:RNA, Messenger; D014746:Vimentin; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate